ARTV - NASDAQ
Artiva Biotherapeutics, Inc.
$6.87
+2.6%Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
At a Glance
Live Snapshotartv
Selling, General and Administrative Expenses
Last Annual Value
20.27M
3-Year CAGR
-1%
5-Year CAGR
36%
10-Year CAGR
16%
Artiva Biotherapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 20.27M | 13.4% | 9.5% | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 26.79M | -2.4% | 22.5% | N/A | |
 CAMP4 Therapeutics Corporation NASDAQ:CAMP | 17.36M | 14.3% | -29.7% | -16.5% | |
 Clene Inc. NASDAQ:CLNN | 9.23M | -13.8% | -13.3% | N/A | |
 Immix Biopharma, Inc. NASDAQ:IMMX | 13.70M | 22.7% | 62.1% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 22.41M | -8.1% | -3.6% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 16.33M | -12.3% | -4.7% | N/A | |
 CEL-SCI Corporation AMEX:CVM | 4.22M | -22.3% | -20.2% | -4.2% | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 311.90K | -81.5% | -61.1% | -25.2% | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 63.12M | 4.7% | -0.4% | 10.0% | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 32.24M | -6.2% | -4.1% | 18.1% |
Artiva Biotherapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ARTV research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.